UK, Clinical TrialUK

Verona's asthma compound goes clinic

25.03.2008

AIM-listed Verona Pharma’s (London) long-acting Phosphodiesterase 3 and 4 inhibitor RPL554 is going to enter clinical trials. After finalisation of an animal toxicological study of the nasally administered drug candidate for the treatment of allergic respiratory diseases, the company announced it aims to begin a combined Phase I/IIa study at the end of June to assess whether the compound is safe and effective in healthy people with stable mild asthma. RPL554 is a long-acting bronchodilator and anti-inflammatory molecule being developed to treat hay fever (rhinitis), asthma and chronic obstructive pulmonary disease. The compound does not use steroids or beta agonists, which are present in many current treatments, but show unwanted side effects or limited effectiveness. Verona Pharma is aiming to partner or licence-out the compound, which targets the US$20 bn respiratory market, in early stage.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/veronas-asthma-compound-goes-clinic.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • SANTHERA80.00 CHF15.4%
  • MAGFORCE6.47 EUR9.7%
  • CYTOS0.27 CHF8.0%

FLOP

  • WILEX2.26 EUR-27.6%
  • MOLOGEN7.30 EUR-22.3%
  • 4SC1.16 EUR-20.0%

TOP

  • SANTHERA80.00 CHF3709.5%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR190.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-68.1%
  • MERCK KGAA64.23 EUR-45.8%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products